Neurology®
The most widely read and highly cited peer-reviewed Neurology journal
Quick Search
Advanced Search
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
Volume 61, Number 4, August 26, 2003
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kaida, K.
Right arrow Articles by Kanazawa, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaida, K.
Right arrow Articles by Kanazawa, I.
Related Collections
Right arrow All Immunology
Right arrow Peripheral neuropathy
Right arrow Guillain-Barre syndrome

Neurology 2003;61:465-470
© 2003 American Academy of Neurology

GalNAc-GD1a in human peripheral nerve

Target sites of anti-ganglioside antibody K. Kaida, MD PhD, S. Kusunoki, MD PhD, K. Kamakura, MD PhD, K. Motoyoshi, MD PhD and I. Kanazawa, MD PhD

From the Third Department of Internal Medicine (Drs. Kaida, Kamakura, and Motoyoshi), National Defense Medical College, Saitama-ken; and the Department of Neurology (Drs. Kusunoki and Kanazawa), School of Medicine, University of Tokyo, Japan.

Address correspondence and reprint requests to Dr. Susumu Kusunoki, Department of Neurology, School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan; e-mail: kusunoki-tky{at}umin.ac.jp

Background: The authors previously reported that immunoglobulin G (IgG) antibody to the ganglioside N-acetylgalactosaminyl GD1a (GalNAc-GD1a) is associated with the pure motor variant of Guillain-Barré syndrome (GBS). Elucidation of the localization of GalNAc-GD1a in human peripheral nerve tissue may lead to understanding of the pathogenetic role of anti-GalNAc-GD1a antibody in GBS.

Methods: IgG anti-GalNAc-GD1a-monospecific antibody was purified from anti-GalNAc-GD1a antibody-positive rabbit sera through an affinity column. Anti-neurofilament-200 monoclonal and anti-HNK-1 monoclonal antibodies were used as the markers for axon and myelin. Immunohistochemical study using double fluorescence labeling technique was conducted in human ventral roots (VR), dorsal roots (DR), intramuscular nerves, and sural nerves. Human teased ventral fibers also were studied.

Results: Anti-GalNAc-GD1a antibody immunostained an inner part of compact myelin and additionally a periaxonal-axolemma-related portion in the VR, small-diameter DR fibers, and IM nerves. In sural nerves, small fibers were selectively stained. In VR, the staining was localized in the paranodal region.

Conclusion: Anti-GalNAc-GD1a antibodies in patients’ sera may bind to those regions in the VR and IM nerves where GalNAc-GD1a is localized, and may function in the pathogenesis of pure motor type GBS. Further investigation is needed to explain the discrepancy between the immunolocalization of GalNAc-GD1a in sensory nerves and the absence of sensory disturbance in patients with GBS with IgG anti-GalNAc-GD1a antibodies.




This article has been cited by other articles:


Home page
GlycobiologyHome page
K. Kaida, T. Ariga, and R. K Yu
Antiganglioside antibodies and their pathophysiological effects on Guillain-Barre syndrome and related disorders--A review
Glycobiology, July 1, 2009; 19(7): 676 - 692.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
K. Kaida, M. Sonoo, G. Ogawa, K. Kamakura, M. Ueda-Sada, M. Arita, K. Motoyoshi, and S. Kusunoki
GM1/GalNAc-GD1a complex: A target for pure motor Guillain-Barre syndrome
Neurology, November 18, 2008; 71(21): 1683 - 1690.
[Abstract] [Full Text] [PDF]